Trial Profile
A Phase I, Open-label, Multicenter Study Investigating the Tolerability and Efficacy of UV1 Vaccine in First-line Malignant Melanoma Patients Planned for Treatment With Pembrolizumab
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 16 Oct 2023
Price :
$35
*
At a glance
- Drugs Granulocyte macrophage colony stimulating factor (Primary) ; Pembrolizumab (Primary) ; UV 1 (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Registrational
- Sponsors Ultimovacs AS
- 12 Oct 2023 According to an Ultimovacs AS media release, the 4-year survival across both cohorts is expected to be announced in Q2 2024.
- 12 Oct 2023 Results presented in an Ultimovacs AS Media Release.
- 28 Jun 2023 Results assessing safety and clinical activity in patients with melanoma, published in the Clinical Cancer Research.